AstraZeneca Initiates P-I Study of AZD7442 Against COVID-19
Shots:
- The first participants have been dosed in a P-I trial of AZD7442 to assess safety- tolerability- and PK of the combination mAbs in up to 48 healthy participants aged 18-55 yrs. in the UK. The study is funded by DARPA
- If AZD7442 proves to be tolerated and has a favorable safety profile in the trial- AstraZeneca will progress it into larger P-II & P-III trials to evaluate its efficacy as a preventative and treatment approach against COVID-19. The company anticipates the results of P-I study in H2’20
- AZD7442 is a combination of two mAbs derived from convalescent patients with SARS-CoV-2 infection- discovered by Vanderbilt University Medical Center and licensed to AstraZeneca in Jun’2020. AstraZeneca optimized the mAbs with half-life extension and reduced Fc receptor binding
Ref: AstraZeneca | Image: Outsourcing Pharma
Click here to read the full press release
Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at [email protected]
